These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1048 related articles for article (PubMed ID: 20926833)

  • 21. Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes.
    Hot A; Miossec P
    Ann Rheum Dis; 2011 May; 70(5):727-32. PubMed ID: 21345813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monocyte derived interleukin (IL)-23 is an important determinant of synovial IL-17A expression in rheumatoid arthritis.
    Stamp LK; Easson A; Pettersson L; Highton J; Hessian PA
    J Rheumatol; 2009 Nov; 36(11):2403-8. PubMed ID: 19797506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin-17 and innate immunity in infections and chronic inflammation.
    Isailovic N; Daigo K; Mantovani A; Selmi C
    J Autoimmun; 2015 Jun; 60():1-11. PubMed ID: 25998834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis.
    Kolbinger F; Loesche C; Valentin MA; Jiang X; Cheng Y; Jarvis P; Peters T; Calonder C; Bruin G; Polus F; Aigner B; Lee DM; Bodenlenz M; Sinner F; Pieber TR; Patel DD
    J Allergy Clin Immunol; 2017 Mar; 139(3):923-932.e8. PubMed ID: 27502297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin 17A as an effective target for anti-inflammatory and antiparasitic treatment of toxoplasmic uveitis.
    Sauer A; Pfaff AW; Villard O; Creuzot-Garcher C; Dalle F; Chiquet C; Pelloux H; Speeg-Schatz C; Gaucher D; Prevost G; Bourcier T; Candolfi E
    J Infect Dis; 2012 Oct; 206(8):1319-29. PubMed ID: 22927448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protective effect of a germline, IL-17-neutralizing antibody in murine models of autoimmune inflammatory disease.
    Dallenbach K; Maurer P; Röhn T; Zabel F; Kopf M; Bachmann MF
    Eur J Immunol; 2015 Apr; 45(4):1238-47. PubMed ID: 25545966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis.
    Patel T; Gordon KB
    Dermatol Ther; 2004; 17(5):427-31. PubMed ID: 15379777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis?
    Lubberts E
    Cytokine; 2008 Feb; 41(2):84-91. PubMed ID: 18039580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study.
    Baslund B; Tvede N; Danneskiold-Samsoe B; Larsson P; Panayi G; Petersen J; Petersen LJ; Beurskens FJ; Schuurman J; van de Winkel JG; Parren PW; Gracie JA; Jongbloed S; Liew FY; McInnes IB
    Arthritis Rheum; 2005 Sep; 52(9):2686-92. PubMed ID: 16142748
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial.
    Genovese MC; Bojin S; Biagini IM; Mociran E; Cristei D; Mirea G; Georgescu L; Sloan-Lancaster J
    Arthritis Rheum; 2013 Apr; 65(4):880-9. PubMed ID: 23359344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IL-27-producing CD14(+) cells infiltrate inflamed joints of rheumatoid arthritis and regulate inflammation and chemotactic migration.
    Tanida S; Yoshitomi H; Ishikawa M; Kasahara T; Murata K; Shibuya H; Ito H; Nakamura T
    Cytokine; 2011 Aug; 55(2):237-44. PubMed ID: 21592822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Briakinumab.
    Lima XT; Abuabara K; Kimball AB; Lima HC
    Expert Opin Biol Ther; 2009 Aug; 9(8):1107-13. PubMed ID: 19569977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Flow cytometric detection of type 1 (IL-2, IFN-gamma) and type 2 (IL-4, IL-5) cytokines in T-helper and T-suppressor/cytotoxic cells in rheumatoid arthritis, allergic asthma and atopic dermatitis.
    Schuerwegh AJ; De Clerck LS; De Schutter L; Bridts CH; Verbruggen A; Stevens WJ
    Cytokine; 1999 Oct; 11(10):783-8. PubMed ID: 10525317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.
    Sfikakis PP
    Curr Dir Autoimmun; 2010; 11():180-210. PubMed ID: 20173395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of monoclonal antibodies targeting interleukin-17 pathway for inflammatory arthritis: a meta-analysis of randomized controlled clinical trials.
    Wei M; Duan D
    Drug Des Devel Ther; 2016; 10():2771-2777. PubMed ID: 27672309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.
    Kimball AB; Gordon KB; Langley RG; Menter A; Chartash EK; Valdes J;
    Arch Dermatol; 2008 Feb; 144(2):200-7. PubMed ID: 18283176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials.
    Dick AD; Tugal-Tutkun I; Foster S; Zierhut M; Melissa Liew SH; Bezlyak V; Androudi S
    Ophthalmology; 2013 Apr; 120(4):777-87. PubMed ID: 23290985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The roles of IL-17A in inflammatory immune responses and host defense against pathogens.
    Iwakura Y; Nakae S; Saijo S; Ishigame H
    Immunol Rev; 2008 Dec; 226():57-79. PubMed ID: 19161416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 1,25-dihydroxyvitamin D3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis.
    Colin EM; Asmawidjaja PS; van Hamburg JP; Mus AM; van Driel M; Hazes JM; van Leeuwen JP; Lubberts E
    Arthritis Rheum; 2010 Jan; 62(1):132-42. PubMed ID: 20039421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.
    Reich K; Blauvelt A; Armstrong A; Langley RG; Fox T; Huang J; Papavassilis C; Liang E; Lloyd P; Bruin G
    Br J Dermatol; 2017 Mar; 176(3):752-758. PubMed ID: 27518376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.